(Q35235621)

7 August 2017

The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems (English)

1 reference

7 August 2017

1 reference

1 reference

Daniel J Cobaugh

1

1 reference

7 August 2017

Carl Gainor

2

1 reference

7 August 2017

Cynthia L Gaston

3

1 reference

7 August 2017

Tai C Kwong

4

1 reference

7 August 2017

Barbarajean Magnani

5

1 reference

7 August 2017

Mary Lynn McPherson

6

1 reference

7 August 2017

Jacob T Painter

7

1 reference

7 August 2017

Edward P Krenzelok

8

1 reference

7 August 2017

1 September 2014

1 reference

American Journal of Health-System Pharmacy

7 August 2017

1 reference

7 August 2017

71

1 reference

7 August 2017

18

1 reference

7 August 2017

1539-1554

1 reference

Pre-emptive analgesia and protective premedication. What is the difference?

7 August 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

31 March 2020

Pre-emptive analgesia

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Do we need preemptive analgesia for the treatment of postoperative pain?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Preemptive analgesia II: recent advances and current trends

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: the role of timing of analgesia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Multimodal analgesia for controlling acute postoperative pain

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

ARE POSTOPERATIVE NARCOTICS NECESSARY?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Studies in pain with the analgesic-demand system

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Managing acute pain in opioid tolerant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Acute pain management for patients receiving maintenance methadone or buprenorphine therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Oral fluid testing: promises and pitfalls

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Pharmacogenetics of opioids

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Evidence that morphine is metabolized to hydromorphone but not to oxymorphone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Anomalous observations of hydrocodone in patients on oxycodone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Anomalous observations of codeine in patients on morphine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

National surveillance of emergency department visits for outpatient adverse drug events

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Patterns of abuse among unintentional pharmaceutical overdose fatalities

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Management of opioid analgesic overdose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Neurotoxicity of meperidine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Opioid-induced delay in gastric emptying: a peripheral mechanism in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

The empiric use of naloxone in patients with altered mental status: a reappraisal

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Opioid receptor polymorphism A118G associated with clinical severity in a drug overdose population

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Methadone and buprenorphine toxicity in children

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Buprenorphine and buprenorphine/naloxone intoxication in children - how strong is the risk?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

The underrecognized toll of prescription opioid abuse on young children

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Whole fentanyl patch ingestion: a multi-center case series

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Oral abuse of fentanyl patches (Duragesic): seven case reports

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Fentanyl intoxication caused by abuse of transdermal fentanyl

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Recurrent respiratory depression associated with fentanyl transdermal patch gel reservoir ingestion.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Transdermal fentanyl in deliberate overdose in pediatrics.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Life-threatening coma and full-thickness sunburn in a patient treated with transdermal fentanyl patches: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Pharmacokinetic evaluation of hydrocodone/acetaminophen for pain management

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Fatalities involving acetaminophen combination products reported to United States poison centers

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Naloxone in opioid poisoning: walking the tightrope

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Medical outcomes associated with nonmedical use of methadone and buprenorphine.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

QTc interval prolongation for patients in methadone maintenance treatment: a five years follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Methadone-Associated QTc Prolongation: A Case Report and Review of the Literature

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

OxyContin abuse and overdose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Toxicology and characteristics of fatal oxycodone toxicity cases in New South Wales, Australia 1999-2008.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Oxycodone overdose causes naloxone responsive coma and QT prolongation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Use and efficacy of nebulized naloxone in patients with suspected opioid intoxication

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Position Paper: Single-Dose Activated Charcoal

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Laboratory testing for prescription opioids

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Prescription drug monitoring programs and death rates from drug overdose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Do prescription monitoring programs impact state trends in opioid abuse/misuse?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

The use of prescription monitoring programs to reduce opioid diversion and improve patient safety

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

A statewide prescription monitoring program affects emergency department prescribing behaviors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Meperidine: a critical review

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Opioid therapies and cytochrome p450 interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

More codeine fatalities after tonsillectomy in North American children.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Project Lazarus: community-based overdose prevention in rural North Carolina

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Psychological comorbidities predicting prescription opioid abuse among patients in chronic pain presenting to the emergency department

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Association between mental health disorders, problem drug use, and regular prescription opioid use.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Prescription drug abuse: executive summary of a policy position paper from the American College of Physicians

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Abusive prescribing of controlled substances--a pharmacy view.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

Diversion of drugs within health care facilities, a multiple-victim crime: patterns of diversion, scope, consequences, detection, and prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP140157

31 March 2020

Identifiers

DOI

10.2146/AJHP140157

1 reference

7 August 2017

1 reference